• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.

作者信息

Wilkinson Samuel T, Sanacora Gerard

机构信息

Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.

The Yale Psychiatric Hospital, Yale New Haven Health, New Haven, Connecticut.

出版信息

JAMA. 2017 Sep 5;318(9):793-794. doi: 10.1001/jama.2017.10697.

DOI:10.1001/jama.2017.10697
PMID:28806440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6248331/
Abstract
摘要

相似文献

1
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.关于氯胺酮用于治疗情绪障碍的超说明书用药考量
JAMA. 2017 Sep 5;318(9):793-794. doi: 10.1001/jama.2017.10697.
2
Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk-Benefit Profile.氯胺酮的非标签使用：一种具有内在不利风险效益特征的具有挑战性的药物治疗模式。
J Clin Pharmacol. 2022 Jan;62(1):10-13. doi: 10.1002/jcph.1983. Epub 2021 Dec 2.
3
Ketamine use in palliative care #132.氯胺酮在姑息治疗中的应用 #132。
J Palliat Med. 2010 Nov;13(11):1381-2. doi: 10.1089/jpm.2010.9763.
4
The semantics of ketamine.氯胺酮的语义学。
Ann Emerg Med. 2001 Jul;38(1):92-5. doi: 10.1067/mem.2001.115943.
5
Ketamine for the treatment of depression: what about the addictive potential?氯胺酮治疗抑郁症：其成瘾潜力如何？
Aust N Z J Psychiatry. 2007 Sep;41(9):772-3.
6
[Compassionate use of intrathecal ketamine for intractable cancer pain].鞘内注射氯胺酮用于难治性癌痛的同情用药
Ann Fr Anesth Reanim. 2013 Sep;32(9):621-2. doi: 10.1016/j.annfar.2013.06.001. Epub 2013 Jul 11.
7
Anaesthetic neurotoxicity in rodents: is the ketamine controversy real?啮齿动物中的麻醉神经毒性：氯胺酮争议是真的吗？
Acta Paediatr. 2007 Nov;96(11):1554-6. doi: 10.1111/j.1651-2227.2007.00436.x. Epub 2007 Aug 20.
8
Electroconvulsive therapy-induced persistent retrograde amnesia: could it be minimised by ketamine or other pharmacological approaches?电抽搐治疗引起的持续逆行性遗忘：氯胺酮或其他药物治疗方法能否减轻？
J Affect Disord. 2010 Oct;126(1-2):39-45. doi: 10.1016/j.jad.2009.11.018. Epub 2010 Jan 8.
9
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.关于使用氯胺酮治疗心境障碍的共识声明。
JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080.
10
Ketamine: a controversial drug for neonates.氯胺酮：一种用于新生儿的有争议的药物。
Semin Perinatol. 2007 Oct;31(5):303-8. doi: 10.1053/j.semperi.2007.07.005.

引用本文的文献

1
Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.阿立哌唑对多巴胺受体信号的微调可抵消氯胺酮的解离作用，但不能抵消其抗抑郁作用。
Transl Psychiatry. 2025 Mar 8;15(1):77. doi: 10.1038/s41398-025-03284-9.
2
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data.家庭环境下、远程医疗支持的氯胺酮治疗抑郁症：真实世界数据的纵向、机器学习和症状网络分析结果。
J Affect Disord. 2024 Sep 15;361:198-208. doi: 10.1016/j.jad.2024.05.131. Epub 2024 May 27.
3
Ketamine for Major Depressive Disorder.氯胺酮治疗重度抑郁症。
Curr Top Behav Neurosci. 2024;66:131-147. doi: 10.1007/7854_2023_453.
4
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.用于治疗抑郁症的氯胺酮和 Esketamine 的关键注意事项：重点关注给药、安全性和耐受性。
Expert Opin Drug Saf. 2022 Jun;21(6):725-732. doi: 10.1080/14740338.2022.2069749. Epub 2022 Apr 29.
5
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.氯胺酮治疗心境障碍和自杀倾向：近期进展的叙述性综述。
Ann Clin Psychiatry. 2022 Feb;34(1):33-43. doi: 10.12788/acp.0048.
6
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.氯胺酮和艾司氯胺酮在抑郁症治疗中的应用：系统评价与荟萃分析概述
Eur J Clin Pharmacol. 2022 Mar;78(3):311-338. doi: 10.1007/s00228-021-03216-8. Epub 2021 Oct 27.
7
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.重复或连续的医学监督氯胺酮给药与肝胆不良事件相关：一项回顾性病例系列研究。
Drug Saf. 2021 Dec;44(12):1365-1374. doi: 10.1007/s40264-021-01120-9. Epub 2021 Oct 26.
8
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.抗抑郁治疗中使用的氯胺酮与精神药物的药效学相互作用：系统评价。
Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. doi: 10.1093/ijnp/pyab039.
9
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.亚胺培南抗抑郁作用的分子机制：超越 NMDA 受体。
Mol Psychiatry. 2022 Jan;27(1):559-573. doi: 10.1038/s41380-021-01121-1. Epub 2021 May 7.
10
Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.单次静脉注射氯胺酮对重性抑郁障碍和创伤后应激障碍的急性认知影响。
Transl Psychiatry. 2021 Apr 8;11(1):205. doi: 10.1038/s41398-021-01327-5.

本文引用的文献

1
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.氯胺酮用于治疗精神疾病的临床非标签使用情况调查。
Am J Psychiatry. 2017 Jul 1;174(7):695-696. doi: 10.1176/appi.ajp.2017.17020239.
2
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.辅助性氯胺酮治疗台湾地区治疗抵抗性抑郁症患者的剂量相关效应。
Neuropsychopharmacology. 2017 Dec;42(13):2482-2492. doi: 10.1038/npp.2017.94. Epub 2017 May 11.
3
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.关于使用氯胺酮治疗心境障碍的共识声明。
JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080.
4
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.静脉注射氯胺酮治疗治疗抵抗性抑郁症的双盲、随机、安慰剂对照、剂量频率研究。
Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: 10.1176/appi.ajp.2016.16010037. Epub 2016 Apr 8.
5
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.氯胺酮和其他 NMDA 拮抗剂：抑郁症的早期临床试验和可能的机制。
Am J Psychiatry. 2015 Oct;172(10):950-66. doi: 10.1176/appi.ajp.2015.15040465.